Concepts (266)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Risperidone | 19 | 2018 | 60 | 7.350 |
Why?
|
| Depressive Disorder, Major | 16 | 2021 | 434 | 5.370 |
Why?
|
| Antipsychotic Agents | 23 | 2024 | 381 | 4.760 |
Why?
|
| Bone Density | 8 | 2023 | 367 | 2.640 |
Why?
|
| Weight Gain | 10 | 2023 | 381 | 2.620 |
Why?
|
| Iron | 6 | 2025 | 302 | 2.390 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 5 | 2023 | 236 | 1.760 |
Why?
|
| Sertraline | 2 | 2024 | 45 | 1.670 |
Why?
|
| Adolescent | 50 | 2025 | 20562 | 1.650 |
Why?
|
| Bone and Bones | 4 | 2017 | 301 | 1.620 |
Why?
|
| Depression | 6 | 2024 | 1333 | 1.610 |
Why?
|
| Anxiety Disorders | 5 | 2019 | 721 | 1.560 |
Why?
|
| Anxiety | 5 | 2025 | 987 | 1.520 |
Why?
|
| Ferritins | 5 | 2024 | 109 | 1.300 |
Why?
|
| Anemia, Iron-Deficiency | 3 | 2025 | 141 | 1.230 |
Why?
|
| Autism Spectrum Disorder | 3 | 2023 | 431 | 1.220 |
Why?
|
| Fluoxetine | 2 | 2024 | 44 | 1.120 |
Why?
|
| alpha7 Nicotinic Acetylcholine Receptor | 2 | 2018 | 56 | 1.110 |
Why?
|
| Child | 38 | 2025 | 25789 | 1.070 |
Why?
|
| Sexual Behavior | 2 | 2021 | 244 | 1.050 |
Why?
|
| Hyperprolactinemia | 3 | 2017 | 23 | 0.930 |
Why?
|
| Puberty | 2 | 2024 | 104 | 0.920 |
Why?
|
| Basal Ganglia | 1 | 2025 | 63 | 0.900 |
Why?
|
| Absorptiometry, Photon | 8 | 2017 | 203 | 0.890 |
Why?
|
| Male | 49 | 2025 | 64922 | 0.890 |
Why?
|
| Metformin | 2 | 2023 | 166 | 0.880 |
Why?
|
| Human Growth Hormone | 1 | 2024 | 75 | 0.860 |
Why?
|
| Metabolic Syndrome | 3 | 2014 | 364 | 0.850 |
Why?
|
| Dietary Supplements | 2 | 2025 | 439 | 0.850 |
Why?
|
| Body Height | 1 | 2024 | 204 | 0.820 |
Why?
|
| Nutrition Surveys | 1 | 2024 | 314 | 0.780 |
Why?
|
| Autonomic Nervous System | 2 | 2023 | 50 | 0.780 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2024 | 323 | 0.780 |
Why?
|
| Humans | 63 | 2025 | 132061 | 0.750 |
Why?
|
| Female | 41 | 2025 | 70712 | 0.710 |
Why?
|
| Mental Disorders | 5 | 2019 | 884 | 0.710 |
Why?
|
| Sexual Dysfunctions, Psychological | 1 | 2021 | 41 | 0.700 |
Why?
|
| Young Adult | 15 | 2023 | 9957 | 0.690 |
Why?
|
| Hyperglycemia | 1 | 2023 | 235 | 0.690 |
Why?
|
| Cognition | 2 | 2025 | 810 | 0.680 |
Why?
|
| Gastrointestinal Microbiome | 2 | 2021 | 811 | 0.680 |
Why?
|
| Movement Disorders | 1 | 2023 | 223 | 0.660 |
Why?
|
| Migraine Disorders | 2 | 2020 | 62 | 0.660 |
Why?
|
| Antidepressive Agents | 1 | 2023 | 327 | 0.650 |
Why?
|
| Steroids | 2 | 2019 | 173 | 0.610 |
Why?
|
| Catatonia | 1 | 2019 | 17 | 0.600 |
Why?
|
| Nephrotic Syndrome | 1 | 2019 | 51 | 0.590 |
Why?
|
| Body Mass Index | 11 | 2023 | 1694 | 0.580 |
Why?
|
| Cyclosporine | 1 | 2019 | 126 | 0.580 |
Why?
|
| Cross-Sectional Studies | 8 | 2025 | 3761 | 0.580 |
Why?
|
| Attention Deficit and Disruptive Behavior Disorders | 2 | 2015 | 45 | 0.580 |
Why?
|
| Sexual Maturation | 1 | 2018 | 46 | 0.570 |
Why?
|
| Calcium Carbonate | 1 | 2017 | 11 | 0.550 |
Why?
|
| Cholecalciferol | 1 | 2017 | 22 | 0.550 |
Why?
|
| Adult Survivors of Child Adverse Events | 1 | 2017 | 15 | 0.530 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2017 | 65 | 0.530 |
Why?
|
| Antifungal Agents | 1 | 2019 | 312 | 0.510 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2017 | 75 | 0.500 |
Why?
|
| Lumbar Vertebrae | 4 | 2023 | 113 | 0.500 |
Why?
|
| Basal Ganglia Diseases | 1 | 2016 | 25 | 0.490 |
Why?
|
| Toxoplasma | 1 | 2016 | 17 | 0.490 |
Why?
|
| Central Nervous System Stimulants | 3 | 2013 | 128 | 0.490 |
Why?
|
| Toxoplasmosis | 1 | 2016 | 23 | 0.490 |
Why?
|
| Obsessive-Compulsive Disorder | 2 | 2023 | 831 | 0.480 |
Why?
|
| Body Fat Distribution | 1 | 2016 | 32 | 0.480 |
Why?
|
| Bacteroidetes | 1 | 2015 | 23 | 0.480 |
Why?
|
| Firmicutes | 1 | 2015 | 22 | 0.480 |
Why?
|
| Problem Behavior | 1 | 2016 | 39 | 0.470 |
Why?
|
| Follow-Up Studies | 7 | 2019 | 5409 | 0.470 |
Why?
|
| Multidetector Computed Tomography | 1 | 2015 | 39 | 0.470 |
Why?
|
| Serotonin Antagonists | 1 | 2015 | 15 | 0.460 |
Why?
|
| Polymorphism, Genetic | 3 | 2021 | 803 | 0.460 |
Why?
|
| Comorbidity | 5 | 2023 | 1609 | 0.450 |
Why?
|
| Diabetes Mellitus | 1 | 2023 | 921 | 0.450 |
Why?
|
| Body Composition | 1 | 2017 | 550 | 0.440 |
Why?
|
| Suicide, Attempted | 1 | 2016 | 154 | 0.430 |
Why?
|
| Gene Deletion | 1 | 2017 | 792 | 0.430 |
Why?
|
| Adiposity | 1 | 2015 | 207 | 0.430 |
Why?
|
| Psychotropic Drugs | 1 | 2015 | 130 | 0.420 |
Why?
|
| Electroconvulsive Therapy | 2 | 2004 | 83 | 0.400 |
Why?
|
| Pilot Projects | 5 | 2021 | 1450 | 0.400 |
Why?
|
| Prolactin | 4 | 2016 | 113 | 0.390 |
Why?
|
| Obesity | 4 | 2023 | 2391 | 0.390 |
Why?
|
| Overweight | 1 | 2016 | 383 | 0.390 |
Why?
|
| Cytokines | 1 | 2018 | 1358 | 0.390 |
Why?
|
| Bipolar Disorder | 1 | 2015 | 369 | 0.370 |
Why?
|
| Neurodevelopmental Disorders | 1 | 2017 | 560 | 0.360 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 1 | 2011 | 49 | 0.360 |
Why?
|
| Isoxazoles | 1 | 2011 | 24 | 0.350 |
Why?
|
| Dextroamphetamine | 1 | 2010 | 6 | 0.340 |
Why?
|
| Methylphenidate | 1 | 2010 | 58 | 0.330 |
Why?
|
| Psychiatric Status Rating Scales | 4 | 2021 | 846 | 0.320 |
Why?
|
| Glycine | 1 | 2010 | 161 | 0.310 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2024 | 1672 | 0.310 |
Why?
|
| Receptors, Dopamine D2 | 1 | 2009 | 41 | 0.300 |
Why?
|
| Prospective Studies | 5 | 2019 | 6567 | 0.300 |
Why?
|
| Linear Models | 3 | 2017 | 713 | 0.290 |
Why?
|
| Leptin | 1 | 2009 | 219 | 0.290 |
Why?
|
| Algorithms | 1 | 2015 | 1728 | 0.280 |
Why?
|
| Treatment Outcome | 9 | 2023 | 13028 | 0.280 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 2 | 2021 | 229 | 0.280 |
Why?
|
| Child, Preschool | 7 | 2018 | 14751 | 0.280 |
Why?
|
| Pyrimidines | 1 | 2011 | 418 | 0.280 |
Why?
|
| Hypertriglyceridemia | 1 | 2009 | 114 | 0.270 |
Why?
|
| Emotions | 3 | 2019 | 365 | 0.250 |
Why?
|
| Longitudinal Studies | 3 | 2021 | 1491 | 0.240 |
Why?
|
| Demography | 2 | 2017 | 240 | 0.230 |
Why?
|
| Imagination | 2 | 2008 | 18 | 0.230 |
Why?
|
| Sex Characteristics | 2 | 2017 | 327 | 0.230 |
Why?
|
| Adult | 11 | 2025 | 31568 | 0.220 |
Why?
|
| Myasthenia Gravis | 1 | 2004 | 69 | 0.210 |
Why?
|
| Methohexital | 1 | 2003 | 3 | 0.210 |
Why?
|
| Methyl Ethers | 1 | 2003 | 23 | 0.210 |
Why?
|
| Mental Processes | 1 | 2003 | 39 | 0.210 |
Why?
|
| Anesthetics, Intravenous | 1 | 2003 | 47 | 0.210 |
Why?
|
| Anesthetics, Inhalation | 1 | 2003 | 46 | 0.200 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 2023 | 26 | 0.200 |
Why?
|
| Severity of Illness Index | 4 | 2018 | 3091 | 0.200 |
Why?
|
| Quinolones | 2 | 2013 | 58 | 0.190 |
Why?
|
| Acceptance and Commitment Therapy | 2 | 2020 | 44 | 0.190 |
Why?
|
| Sex Factors | 2 | 2019 | 1353 | 0.180 |
Why?
|
| Orgasm | 1 | 2021 | 7 | 0.180 |
Why?
|
| Receptor, Serotonin, 5-HT2A | 1 | 2021 | 11 | 0.180 |
Why?
|
| Cohort Studies | 2 | 2024 | 5164 | 0.180 |
Why?
|
| Interpersonal Relations | 1 | 2003 | 227 | 0.180 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2017 | 1247 | 0.180 |
Why?
|
| Cardiovascular Diseases | 1 | 2014 | 2092 | 0.170 |
Why?
|
| Mental Health | 1 | 2024 | 371 | 0.170 |
Why?
|
| Qualitative Research | 1 | 2024 | 669 | 0.170 |
Why?
|
| Double-Blind Method | 2 | 2017 | 1659 | 0.170 |
Why?
|
| Piperazines | 2 | 2013 | 257 | 0.170 |
Why?
|
| Drug Therapy, Combination | 2 | 2015 | 1180 | 0.160 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2021 | 394 | 0.160 |
Why?
|
| Adolescent Behavior | 1 | 2021 | 172 | 0.160 |
Why?
|
| Avoidance Learning | 1 | 2019 | 60 | 0.150 |
Why?
|
| Respiratory Sinus Arrhythmia | 1 | 2018 | 10 | 0.150 |
Why?
|
| Multivariate Analysis | 2 | 2013 | 1436 | 0.150 |
Why?
|
| Problem-Based Learning | 1 | 2019 | 75 | 0.150 |
Why?
|
| Permeability | 1 | 2018 | 122 | 0.150 |
Why?
|
| Risk Factors | 4 | 2019 | 10941 | 0.140 |
Why?
|
| Drug Resistance | 1 | 2019 | 252 | 0.140 |
Why?
|
| Prevalence | 2 | 2017 | 2658 | 0.140 |
Why?
|
| Time Factors | 3 | 2018 | 6448 | 0.140 |
Why?
|
| Seizures | 1 | 2003 | 893 | 0.140 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2017 | 2172 | 0.140 |
Why?
|
| Biomarkers | 2 | 2021 | 3406 | 0.140 |
Why?
|
| Calcium, Dietary | 1 | 2017 | 38 | 0.140 |
Why?
|
| Observational Studies as Topic | 1 | 2017 | 105 | 0.130 |
Why?
|
| Inflammation | 2 | 2021 | 1517 | 0.120 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2025 | 3834 | 0.120 |
Why?
|
| Interleukin-6 | 2 | 2021 | 433 | 0.120 |
Why?
|
| Asymptomatic Infections | 1 | 2016 | 38 | 0.120 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2018 | 540 | 0.120 |
Why?
|
| Iron Metabolism Disorders | 1 | 2015 | 12 | 0.120 |
Why?
|
| Aggression | 2 | 2023 | 227 | 0.120 |
Why?
|
| Regression Analysis | 1 | 2017 | 792 | 0.120 |
Why?
|
| Brain | 2 | 2008 | 3183 | 0.120 |
Why?
|
| Social Perception | 2 | 2008 | 56 | 0.120 |
Why?
|
| Serologic Tests | 1 | 2016 | 130 | 0.120 |
Why?
|
| Interview, Psychological | 1 | 2016 | 108 | 0.120 |
Why?
|
| Intra-Abdominal Fat | 1 | 2016 | 61 | 0.120 |
Why?
|
| Statistics as Topic | 1 | 2016 | 253 | 0.120 |
Why?
|
| X-Ray Microtomography | 1 | 2015 | 96 | 0.110 |
Why?
|
| Blood Glucose | 3 | 2023 | 1123 | 0.110 |
Why?
|
| Phantoms, Imaging | 1 | 2015 | 147 | 0.110 |
Why?
|
| Logistic Models | 1 | 2019 | 1838 | 0.110 |
Why?
|
| Vitamin D | 1 | 2016 | 183 | 0.110 |
Why?
|
| ROC Curve | 1 | 2016 | 601 | 0.110 |
Why?
|
| Osteoporosis | 1 | 2015 | 136 | 0.110 |
Why?
|
| Case-Control Studies | 2 | 2023 | 3418 | 0.100 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2014 | 148 | 0.100 |
Why?
|
| DNA Copy Number Variations | 1 | 2018 | 1032 | 0.100 |
Why?
|
| Radiography | 1 | 2015 | 819 | 0.100 |
Why?
|
| Skinfold Thickness | 1 | 2012 | 34 | 0.100 |
Why?
|
| Signal Transduction | 1 | 2024 | 4703 | 0.090 |
Why?
|
| Prognosis | 2 | 2019 | 5009 | 0.090 |
Why?
|
| Conduct Disorder | 1 | 2011 | 32 | 0.090 |
Why?
|
| Cytochrome P-450 CYP2D6 Inhibitors | 1 | 2011 | 3 | 0.090 |
Why?
|
| Paliperidone Palmitate | 1 | 2011 | 4 | 0.090 |
Why?
|
| Homeostasis | 1 | 2015 | 721 | 0.090 |
Why?
|
| Sexual Development | 1 | 2011 | 24 | 0.090 |
Why?
|
| Cytochrome P-450 CYP2D6 | 1 | 2011 | 34 | 0.090 |
Why?
|
| Polypharmacy | 1 | 2011 | 36 | 0.090 |
Why?
|
| Calcium | 1 | 2016 | 1078 | 0.080 |
Why?
|
| Pharmacogenetics | 1 | 2011 | 200 | 0.080 |
Why?
|
| Pregnancy Outcome | 1 | 2013 | 637 | 0.080 |
Why?
|
| Child Development Disorders, Pervasive | 1 | 2011 | 82 | 0.080 |
Why?
|
| Depressive Disorder | 1 | 2013 | 476 | 0.080 |
Why?
|
| Radius | 1 | 2010 | 36 | 0.080 |
Why?
|
| Growth | 1 | 2010 | 95 | 0.080 |
Why?
|
| Psychotic Disorders | 1 | 2011 | 150 | 0.080 |
Why?
|
| Anthropometry | 1 | 2010 | 194 | 0.080 |
Why?
|
| Retrospective Studies | 4 | 2023 | 17419 | 0.080 |
Why?
|
| United States | 1 | 2024 | 11658 | 0.070 |
Why?
|
| Waist Circumference | 1 | 2009 | 95 | 0.070 |
Why?
|
| DNA Primers | 1 | 2009 | 636 | 0.070 |
Why?
|
| Pregnancy Complications | 1 | 2013 | 552 | 0.070 |
Why?
|
| Child Behavior Disorders | 1 | 2009 | 70 | 0.070 |
Why?
|
| Linkage Disequilibrium | 1 | 2009 | 316 | 0.070 |
Why?
|
| Oxygen Radioisotopes | 2 | 2008 | 4 | 0.070 |
Why?
|
| Tic Disorders | 1 | 2009 | 80 | 0.070 |
Why?
|
| Schizophrenic Psychology | 1 | 2008 | 85 | 0.070 |
Why?
|
| Fractures, Bone | 1 | 2010 | 205 | 0.070 |
Why?
|
| Drug Administration Schedule | 1 | 2009 | 749 | 0.070 |
Why?
|
| Gene Frequency | 1 | 2009 | 749 | 0.070 |
Why?
|
| Cholesterol, HDL | 1 | 2009 | 398 | 0.070 |
Why?
|
| Functional Laterality | 2 | 2008 | 192 | 0.070 |
Why?
|
| Insulin Resistance | 1 | 2012 | 697 | 0.060 |
Why?
|
| Alleles | 1 | 2011 | 1686 | 0.060 |
Why?
|
| Blood Pressure | 1 | 2012 | 1400 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 1 | 2009 | 1548 | 0.060 |
Why?
|
| Brain Mapping | 2 | 2008 | 403 | 0.060 |
Why?
|
| Genotype | 1 | 2011 | 2697 | 0.060 |
Why?
|
| Base Sequence | 1 | 2009 | 2899 | 0.060 |
Why?
|
| Middle Aged | 4 | 2020 | 28964 | 0.060 |
Why?
|
| Schizophrenia | 1 | 2008 | 333 | 0.060 |
Why?
|
| Genetic Variation | 1 | 2011 | 1580 | 0.060 |
Why?
|
| Child Psychiatry | 1 | 2024 | 16 | 0.060 |
Why?
|
| Testosterone | 1 | 2010 | 611 | 0.050 |
Why?
|
| Secondary Prevention | 1 | 2005 | 223 | 0.050 |
Why?
|
| Cognition Disorders | 1 | 2008 | 568 | 0.050 |
Why?
|
| Aged, 80 and over | 1 | 2015 | 7102 | 0.050 |
Why?
|
| Tomography, Emission-Computed | 1 | 2003 | 37 | 0.050 |
Why?
|
| Aging | 1 | 2011 | 1250 | 0.050 |
Why?
|
| Thinking | 1 | 2003 | 34 | 0.050 |
Why?
|
| Interrupted Time Series Analysis | 1 | 2023 | 28 | 0.050 |
Why?
|
| Acceleration | 1 | 2023 | 27 | 0.050 |
Why?
|
| Awareness | 1 | 2003 | 80 | 0.050 |
Why?
|
| Drug Monitoring | 1 | 2024 | 174 | 0.050 |
Why?
|
| Interviews as Topic | 1 | 2024 | 425 | 0.050 |
Why?
|
| Aripiprazole | 2 | 2013 | 22 | 0.050 |
Why?
|
| Water | 1 | 2003 | 195 | 0.050 |
Why?
|
| Self Concept | 1 | 2003 | 164 | 0.050 |
Why?
|
| Models, Neurological | 1 | 2003 | 208 | 0.050 |
Why?
|
| Social Behavior | 1 | 2003 | 222 | 0.050 |
Why?
|
| Resistin | 1 | 2021 | 30 | 0.040 |
Why?
|
| Cholesterol | 1 | 2023 | 558 | 0.040 |
Why?
|
| Nerve Net | 1 | 2003 | 263 | 0.040 |
Why?
|
| Psychotherapy, Group | 1 | 2020 | 59 | 0.040 |
Why?
|
| Hemodynamics | 1 | 2003 | 855 | 0.040 |
Why?
|
| Machine Learning | 1 | 2023 | 346 | 0.040 |
Why?
|
| Pituitary-Adrenal System | 1 | 2019 | 44 | 0.040 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2019 | 68 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2021 | 664 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2009 | 3350 | 0.040 |
Why?
|
| Exercise | 1 | 2023 | 857 | 0.030 |
Why?
|
| Patient Education as Topic | 1 | 2020 | 459 | 0.030 |
Why?
|
| Infant | 1 | 2010 | 13064 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2019 | 1234 | 0.030 |
Why?
|
| Stress, Psychological | 1 | 2019 | 574 | 0.030 |
Why?
|
| Patient Admission | 1 | 2013 | 184 | 0.020 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2013 | 180 | 0.020 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2013 | 242 | 0.020 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2013 | 335 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2019 | 3990 | 0.020 |
Why?
|
| Control Groups | 1 | 2008 | 11 | 0.020 |
Why?
|
| Verbal Behavior | 1 | 2008 | 52 | 0.020 |
Why?
|
| Intention | 1 | 2008 | 101 | 0.020 |
Why?
|
| Reading | 1 | 2008 | 78 | 0.020 |
Why?
|
| Age Factors | 1 | 2013 | 2912 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2008 | 308 | 0.020 |
Why?
|
| Aged | 1 | 2004 | 21406 | 0.020 |
Why?
|
| Cerebrovascular Circulation | 1 | 2008 | 476 | 0.010 |
Why?
|
| Neuropsychological Tests | 1 | 2008 | 991 | 0.010 |
Why?
|
| Pregnancy | 1 | 2013 | 7566 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2013 | 8549 | 0.010 |
Why?
|